Disclosed are a resin composition comprising 20 to 50 mass % of a polyphenylene ether-based resin (a), 0.1 to 9 mass % of a polyphenylene ether-based resin modified with an unsaturated carboxylic acid or acid anhydride thereof (b), 15 to 50 mass % of a homopolystyrene (c), 1 to 25 mass % of one or more selected from the group consisting of a hydrogenated block copolymer (d-1) and a rubber-modified polystyrene (d-2), and 5 to 35 mass % of glass fibers (e) which are surface-treated, a resin composition comprising 20 to 50 mass % of a polyphenylene ether-based resin (a), 15 to 50 mass % of a homopolystyrene (c), 5 to 35 mass % of glass fibers (e), and 0.01 to 1 mass % of compounds (f), a method of producing the same, a molded article, and a mechanical component and housing.

The invention relates to diacyl derivatives of certain polyether polymers, compositions comprising the same, and methods of making the same via reaction with substituted or unsubstituted cyclic anhydrides, and methods of using the same.

Provided herein are extended release polymers. In one aspect, a composition for sustained release of active ingredients comprises a block polymer having formula: PEG-PCL-PLA-PCL-PEG or PGA-PCL-PEG-PCL-PGA. The extended release block polymers modulate drug release rate based on the hydrophobicity of the PTSgel polymer irrespective of the nature of drug. PTSgel polymers are biodegradable, thermosensitive, and compatible with hydrophilic, hydrophobic, and combinations thereof, biologic or chemical active agents.

A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L.sup.D-D, the protein based recognition-molecule being connected to the polymeric carrier by L.sup.P. Each occurrence of D is independently a therapeutic agent having a molecular weight ≦5 kDa. L.sup.D and L.sup.P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

The present invention describes method of preparation of esters or amides of lactyl lactates of general formula I, where Z denotes to group of R—O or RR′—N and R represent alkyl, aryl or H from lactide and the lactide is in contact with a hydrocarbyl alcohol and a hydrolyzable halide in a non-chlorinated organic solvent, or an amine initiated by a hydrolysable halide or hydrogen halide solution or an ammonium hydrohalide, wherein the hydrocarbyl alcohol or amine is either aliphatic or aromatic and containing 1 to 1000 carbon atoms, preferably 1 up to 150 carbon atoms, and optionally one or more, preferably 1 to 5, —CH.sub.2— groups may be replaced by —O— groups.

Structure for annotation

##STR00001##

A stable dispersant and an application thereof in preparing copolymer polyols, the preparation method for the stable dispersant including the steps of 1) contacting a polyol with a dianhydride compound for reaction so as to prepare an adduct; 2) performing a ring-opening addition reaction on the adduct obtained in step 1) and an epoxy compound to prepare a stable dispersant; the dianhydride compound does not contain a double bond that may copolymerize with an olefinically unsaturated monomer, while the epoxy compound contains a double bond that may copolymerize with an olefinically unsaturated monomer, the polyol is a polyester polyol and/or a polyether polyol, preferably being a polyether polyol. The stable dispersant obtained by means of the described preparation method has a multi-active site anchoring function, and is applied to the synthesis of copolymer polyols to obtain copolymer polyols having relatively uniform particle size.

The present invention aims to provide a photochromic compound capable of exhibiting photochromic properties regardless of matrix, and the compound is stably dispersed without aggregation in a process of molding (curing) an optical base material. According to the present invention, a polymer photochromic compound, which has a block polymeric group of an oligomeric chain group having relatively favorable compatibility with a solid matrix and an oligomeric chain group having poor compatibility with a solid matrix, forms a nano- to micro-phase separation structure in a solid matrix. The compound does not rely on the solid matrix, its dispersibility is improved and aggregation is prevented or reduced, whereby excellent photochromic properties can be exhibited.

The present invention discloses a hypocrellin derivative substituted both in a pen-position and in a 2-position by an amino, and a preparation method and use thereof. A general structural formula of the derivative is as represented by formulas I-a to I-d: ##STR00001## The hypocrellin derivative substituted both in a peri-position and in a 2-position by an amino prepared in the present invention has a maximum absorption wavelength of 600-650 nm and a molar extinction coefficient reaching about 20000-40000 M.sup.−1cm.sup.−1. Compared with unmodified hypocrellin or hypocrellin having only a 2-position modified, an absorption spectrum of the derivative is significantly red-shifted and the molar extinction coefficient is greatly improved, and the derivative can efficiently produce reactive oxygen species such as singlet oxygen in a photosensitive condition. In the same condition, the hypocrellin derivative substituted both in a pen-position and in a 2-position by an amino involved in the present invention, when used as a photosensitizer, has a stronger ability to photo-dynamically inactivate tumor cells than the first and second generation commercial photosensitizers.

Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.

The present disclosure provides nanostructure compositions and methods of producing nanostructure compositions. The nanostructure compositions comprise at least one population of nanostructures, at least one poly(alkylene oxide) ligand bound to the surface of the nanostructures, and optionally at least one organic resin. The present disclosure also provides nanostructure films comprising a nanostructure layer and methods of making nanostructure films.